IntelGenx Receives CIPO Notice of Allowance for Loxapine VersaFilm™ Patent
July 05 2018 - 8:00AM
IntelGenx Corp. (TSXV:IGX) (OTCQX:IGXT) (“IntelGenx” or the
“Company”), a leading oral drug delivery company primarily focused
on the development and manufacturing of innovative pharmaceutical
oral films based on its proprietary VersaFilm
™
technology platform, today announced that the Canadian Intellectual
Property Office (“CIPO”) recently issued a Notice of Allowance
(“NoA”) for the Company’s Canadian Patent Application Number
2,998,223 entitled “Loxapine Film Oral Dosage Form”, covering the
use of loxapine in an oral transmucosal film for the treatment of
schizophrenia or bipolar 1 disorder. This is the Company’s first
patent allowed in Canada and the Company’s first Canadian patent
for its VersaFilm™ technology.
Upon issuance, the patent will grant exclusivity
protection in Canada for IntelGenx’s Loxapine VersaFilm™ product
for the treatment of schizophrenia or bipolar 1 disorder through
2037. This is also the Company’s first patent application to
receive NoA in relation to its Loxapine VersaFilm™ project.
“This Notice of Allowance from CIPO is a
significant development in our Loxapine VersaFilm™ project as it
confirms our leading approach in developing oral films to provide
patients with alternative oral treatment solutions,” said Dr. Horst
G. Zerbe, President and CEO of IntelGenx.
About Loxapine
VersaFilm™:
Loxapine VersaFilm™ is the first innovative oral
thin film of loxapine for use in patients with agitation associated
with schizophrenia and bipolar 1 disorder. Loxapine VersaFilm™
utilizes IntelGenx’s proprietary VersaFilm™ technology, allowing
for an improved drug product which addresses unmet medical needs in
schizophrenia and bipolar 1 disorder.
Agitation associated with schizophrenia or
bipolar mania is not uncommon and can rapidly escalate into
physically aggressive behavior that can be potentially dangerous to
the agitated individual and others if left untreated. In a clinical
setting, agitation associated with schizophrenia and bipolar mania
are often effectively managed with behavioral and psychological
techniques, with unexpected acute agitation typically being treated
with parenterally administered sedatives such as benzodiazepines
and/or antipsychotic drugs such as olanzapine and ziprasidone.
About IntelGenx:
Established in 2003, IntelGenx is a leading oral
drug delivery company primarily focused on the development and
manufacturing of innovative pharmaceutical oral films based on its
proprietary VersaFilm™ technology platform.
IntelGenx’s highly skilled team provides
comprehensive pharmaceuticals services to pharmaceutical partners,
including R&D, analytical method development, clinical
monitoring, IP and regulatory services. IntelGenx’s
state-of-the-art manufacturing facility, established for the
VersaFilm™ technology platform, supports lab-scale to pilot and
commercial-scale production, offering full service capabilities to
its clients. More information about the company can be found at
www.intelgenx.com.
Forward Looking Statements:
This document may contain forward-looking
information about IntelGenx’s operating results and business
prospects that involve substantial risks and uncertainties.
Statements that are not purely historical are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and Section 27A of the Securities
Act of 1933, as amended. These statements include, but are not
limited to, statements about IntelGenx’s plans, objectives,
expectations, strategies, intentions or other characterizations of
future events or circumstances and are generally identified by the
words "may," "expects," "anticipates," "intends," "plans,"
"believes," "seeks," "estimates," "could," "would," and similar
expressions. All forward looking statements are expressly qualified
in their entirety by this cautionary statement. Because these
forward-looking statements are subject to a number of risks and
uncertainties, IntelGenx’s actual results could differ materially
from those expressed or implied by these forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, those discussed under
the heading "Risk Factors" in IntelGenx’s annual report on Form
10-K, filed with the United States Securities and Exchange
Commission and available at www.sec.gov, and also filed with
Canadian securities regulatory authorities and www.sedar.com.
IntelGenx assumes no obligation to update any such forward-looking
statements.
Each of the TSX Venture Exchange and OTCQX has neither approved
nor disapproved the contents of this press release. Neither TSX
Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
Source: IntelGenx Technologies Corp.
Contacts :
Stephen Kilmer
Investor Relations
(514) 331-7440 ext. 232
stephen@intelgenx.com
Andre Godin, CPA, CA
Executive Vice-President and CFO
IntelGenx Corp.
(514) 331-7440 ext. 203
andre@intelgenx.com
Intelgenx Technologies (TSXV:IGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Intelgenx Technologies (TSXV:IGX)
Historical Stock Chart
From Sep 2023 to Sep 2024